Biotoscana Investments S.A. Sustainability Profile
Biotoscana Investments S.A., commonly referred to as Biotoscana, is a prominent player in the pharmaceutical and biotechnology industry, headquartered in Uruguay (UY). Founded in 2013, the company has rapidly expanded its operations across Latin America, focusing on the development, manufacturing, and distribution of innovative healthcare solutions. Biotoscana is renowned for its diverse portfolio of specialty pharmaceuticals, particularly in the fields of oncology, rare diseases, and central nervous system disorders. The company distinguishes itself through its commitment to high-quality products and a robust pipeline of new therapies. With a strong market presence, Biotoscana has achieved significant milestones, including strategic partnerships and a growing footprint in key regional markets, solidifying its position as a leader in the biopharmaceutical sector.
DitchCarbon Score
How does Biotoscana Investments S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biotoscana Investments S.A.'s score of 28 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biotoscana Investments S.A.'s reported carbon emissions
Biotoscana Investments S.A., headquartered in Uruguay (UY), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Knight Therapeutics Inc., which may influence its climate-related strategies and reporting. Despite the lack of direct emissions data, Biotoscana's climate commitments and reduction initiatives are not explicitly outlined. There are no documented reduction targets or climate pledges available, suggesting that the company may still be in the early stages of formalising its climate strategy. As a subsidiary, Biotoscana may align its environmental goals with those of Knight Therapeutics Inc., which could include broader industry standards and practices. However, without specific data or commitments, it is challenging to assess their current climate impact or future objectives. In summary, while Biotoscana Investments S.A. does not provide emissions data or specific climate commitments, its relationship with Knight Therapeutics Inc. may play a role in shaping its environmental strategies moving forward.
How Carbon Intensive is Biotoscana Investments S.A.'s Industry?
How Carbon Intensive is Biotoscana Investments S.A.'s Location?
Biotoscana Investments S.A.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biotoscana Investments S.A. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
